(-0.12%) 5 302.00 points
(-0.02%) 40 134 points
(-0.20%) 18 468 points
(0.45%) $81.72
(-1.51%) $1.692
(0.16%) $2 216.30
(-0.83%) $24.55
(-0.26%) $907.30
(0.44%) $0.928
(0.72%) $10.85
(0.37%) $0.794
(-0.10%) $92.35
Live Chart Being Loaded With Signals
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma...
Stats | |
---|---|
Today's Volume | 4.85M |
Average Volume | 1.64M |
Market Cap | 210.38M |
EPS | $0 ( 2024-03-20 ) |
Next earnings date | ( $0 ) 2024-05-07 |
Last Dividend | $0.150 ( 2012-12-18 ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.85 |
ATR14 | $0.0510 (4.95%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-07-31 | Bradrick Brittany | Sell | 27 380 | Common Stock, $0.001 par value |
2023-07-31 | Bradrick Brittany | Sell | 86 301 | Stock Option (Right to Buy) |
2023-07-31 | Mcgahan Keith M | Sell | 195 485 | Common Stock, $0.001 par value |
2023-07-31 | Mcgahan Keith M | Sell | 386 057 | Common Stock, $0.001 par value |
2023-07-31 | Mcgahan Keith M | Sell | 778 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-22.47 |
Last 97 transactions |
Buy: 24 888 642 | Sell: 15 180 768 |
Volume Correlation
Spectrum Pharmaceuticals Correlation
10 Most Positive Correlations | |
---|---|
IRMD | 0.941 |
IDCC | 0.939 |
SLMBP | 0.939 |
DRNA | 0.933 |
PRAA | 0.924 |
MESA | 0.923 |
PIRS | 0.923 |
GALT | 0.922 |
HLIO | 0.92 |
IOAC | 0.919 |
10 Most Negative Correlations | |
---|---|
GMII | -0.923 |
AVIR | -0.911 |
TUEM | -0.907 |
JRJC | -0.896 |
AFYA | -0.896 |
EAR | -0.887 |
GSMG | -0.885 |
DTSS | -0.883 |
ATSG | -0.881 |
GOEV | -0.88 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Spectrum Pharmaceuticals Correlation - Currency/Commodity
Spectrum Pharmaceuticals Financials
Annual | 2022 |
Revenue: | $10.11M |
Gross Profit: | $8.32M (82.28 %) |
EPS: | $-0.430 |
Q1 | 2023 |
Revenue: | $15.62M |
Gross Profit: | $14.55M (93.19 %) |
EPS: | $-0.0255 |
Q4 | 2022 |
Revenue: | $10.11M |
Gross Profit: | $8.32M (82.28 %) |
EPS: | $-0.0488 |
Q3 | 2022 |
Revenue: | $0 |
Gross Profit: | $-3 000.00 (0.00 %) |
EPS: | $-0.120 |
Financial Reports:
No articles found.
Spectrum Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.150 | 2012-12-18 |
Last Dividend | $0.150 | 2012-12-18 |
Next Dividend | $0 | N/A |
Payout Date | 2012-12-28 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.150 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $0.150 | 1.02% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -1.400 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.334 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -1.193 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.71 | 0.800 | 1.449 | 1.159 | [1 - 3] |
quickRatioTTM | 2.31 | 0.800 | 1.124 | 0.899 | [0.8 - 2.5] |
cashRatioTTM | 1.347 | 1.500 | 3.63 | 5.44 | [0.2 - 2] |
debtRatioTTM | 0.275 | -1.500 | 5.42 | -8.12 | [0 - 0.6] |
interestCoverageTTM | -19.33 | 1.000 | -8.27 | -8.27 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.320 | 2.00 | -0.107 | -0.214 | [0 - 30] |
freeCashFlowPerShareTTM | -0.322 | 2.00 | -0.161 | -0.322 | [0 - 20] |
debtEquityRatioTTM | 1.105 | -1.500 | 5.58 | -8.37 | [0 - 2.5] |
grossProfitMarginTTM | 0.889 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -1.481 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -2.18 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.239 | 0.800 | -1.740 | -1.392 | [0.5 - 2] |
Total Score | -3.02 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -5.75 | 1.000 | -0.682 | 0 | [1 - 100] |
returnOnEquityTTM | -1.193 | 2.50 | -9.24 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.322 | 2.00 | -0.107 | -0.322 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.320 | 2.00 | -0.107 | -0.214 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.583 | 1.500 | 9.45 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -2.51 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -1.111 |
Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators